Evogene (EVGN) Q2 2026 Earnings Call Transcript

Evogene reported Q2 2026 net loss of $1.8M, a 62% improvement from the $4.7M loss a year earlier, alongside higher cash discipline (Q2 cash usage $2.1M; cash balance $9.3M at June 30, 2026). The company guided 2026 cash usage to $8.5M–$9.5M (vs. $14.4M in 2025 and $20.5M in 2024) while expanding ChemPass AI’s virtual chemical space to 110B molecules (from 36B) and claiming AI agents can automate tasks in minutes. Operationally, it holds 6 active pharma collaborations (4 new since start of 2026) and projects continued pipeline progression (two pharma programs completed Hit ID; internal program advanced to Lead Optimization). Overall, the financial turnaround and AI progress are offset by revenue declines ($0.7M in H1 2026 vs. $2.9M in H1 2025) and ongoing dilution/runway management via an ATM.

Analysis

The equity story is less about current operating leverage than about whether management can convert a shrinking cash-burning biotech platform into a repeatable discovery business before dilution reclaims the upside. The balance-sheet improvement is real, but the market will likely discount it unless external revenue becomes recurring rather than milestone-choppy; otherwise the ATM remains the effective valuation ceiling. The biggest second-order positive is a potential multiple shift if ChemPass starts to look like a low-capex discovery service with R&D fees, not a conventional pre-revenue biotech.

Competitively, the company is trying to sit between CROs, small-cap AI-drug-discovery peers, and in-house pharma teams. That is a crowded narrative, so the real differentiator is biological validation, not model size or workflow automation; the failed herbicide target is a reminder that computational speed does not fix target-quality risk. If they keep landing pharma partnerships, the likely winners are the infrastructure layer and broader AI stack providers like GOOGL/Cloud exposure, while legacy non-core ag/biotech assets and broad biotech beta are less relevant to the upside.

Near term, the stock should trade on governance resolution, ATM cadence, and whether larger pharma partners show up with fee-bearing work over the next 1-3 months. Over 6-18 months, the inflection is preclinical entry from internal programs; absent that, this remains a financing-and-execution story. The thesis is falsified if cash usage re-accelerates, the ATM becomes routine, or there is no conversion of current collaborations into paid expansion by the next reporting cycle.

Key Decisions for Investors

• Tactically long EVGN/EVRRF only on post-call weakness and only if the board fight resolves without a disruptive change; target a 1-3 month move on governance clarity and partnership headlines, but cut if ATM usage accelerates.
• Pair long EVGN vs short XBI for a 1-3 month catalyst trade: EVGN has idiosyncratic partnership upside, while XBI gives cleaner biotech-beta hedge if the market rotates away from speculative duration assets.
• If options are liquid enough, use a modest EVGN call spread into the board-vote window rather than common stock; the pay-off is re-rating on a successful governance outcome, but implied dilution makes outright longs less attractive.
• Do not add size until there is evidence of a fee-bearing collaboration with a larger pharma partner; that is the key proof point that would justify a higher multiple versus pure milestone optionality.